Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$16.71 -0.3%	$17.69	$13.53 ▼ $35.25	$1.69B	2.09	1.48 million shs	1.34 million shs
CNTA Centessa Pharmaceuticals	$13.00 +4.6%	$12.72	$8.46 ▼ $19.09	$1.66B	1.48	717,908 shs	942,018 shs
GLPG Galapagos	$27.05 -1.3%	$27.29	$22.36 ▼ $31.23	N/A	0.07	249,839 shs	472,306 shs
MNMD Mind Medicine (MindMed)	$6.64 -5.8%	$6.79	$4.70 ▼ $10.44	$532.65M	2.52	1.35 million shs	1.89 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-0.30%	+0.54%	-0.71%	-28.04%	-27.16%
CNTA Centessa Pharmaceuticals	+4.59%	+3.17%	+1.01%	-17.77%	+42.86%
GLPG Galapagos	-1.35%	-6.08%	-5.85%	+5.95%	+5.05%
MNMD Mind Medicine (MindMed)	-5.82%	-7.00%	-9.04%	-2.06%	-9.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.952 of 5 stars	4.5	1.0	1.5	2.5	0.6
CNTA Centessa Pharmaceuticals	3.5366 of 5 stars	4.5	2.0	2.1	3.3	0.6
GLPG Galapagos	0.2479 of 5 stars	0.8	2.0	1.8	0.0	0.6
MNMD Mind Medicine (MindMed)	1.4357 of 5 stars	3.6	0.0	1.4	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	191.74% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.89	114.53% Upside
GLPG Galapagos	1.50	Reduce	$25.33	-6.35% Downside
MNMD Mind Medicine (MindMed)	3.27	Buy	$25.50	284.04% Upside

Current Analyst Ratings Breakdown

Latest MNMD, GLPG, CNTA, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	CNTA Centessa Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/13/2025	MNMD Mind Medicine (MindMed)	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/8/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$6.00
5/8/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
4/7/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/31/2025	CNTA Centessa Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$38.00
3/28/2025	BEAM Beam Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$42.00 ➝ $42.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	26.45	N/A	N/A	$8.86 per share	1.89
CNTA Centessa Pharmaceuticals	$6.85M	253.45	N/A	N/A	$3.05 per share	4.26
GLPG Galapagos	$298.31M	N/A	$0.72 per share	37.76	$47.57 per share	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$3.21 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.81	N/A	N/A	N/A	N/A	-40.22%	-29.95%	8/12/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
MNMD Mind Medicine (MindMed)	-$108.68M	-$1.29	N/A	N/A	N/A	N/A	-40.33%	-32.13%	8/12/2025 (Estimated)

Latest MNMD, GLPG, CNTA, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	-$0.35	+$0.01	-$0.35	N/A	N/A
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
4/23/2025	Q1 2025	GLPG Galapagos	-$0.23	-$2.47	-$2.24	-$2.45	$72.22 million	$97.33 million
3/24/2025	Q4 2024	CNTA Centessa Pharmaceuticals	-$0.38	-$0.34	+$0.04	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	8.81	8.81
CNTA Centessa Pharmaceuticals	0.28	14.37	14.37
GLPG Galapagos	N/A	7.95	7.86
MNMD Mind Medicine (MindMed)	0.10	7.27	7.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CNTA Centessa Pharmaceuticals	82.01%
GLPG Galapagos	32.46%
MNMD Mind Medicine (MindMed)	27.91%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
CNTA Centessa Pharmaceuticals	7.09%
GLPG Galapagos	2.91%
MNMD Mind Medicine (MindMed)	2.26%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.55 million	124.09 million	Optionable
GLPG Galapagos	1,310	N/A	N/A	Optionable
MNMD Mind Medicine (MindMed)	40	75.55 million	73.85 million	Optionable

MNMD, GLPG, CNTA, and BEAM Headlines

Recent News About These Companies

Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Up 6.3% - Here's Why

June 18, 2025 | marketbeat.com

Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 4.8% - Here's Why

June 11, 2025 | marketbeat.com

Equities Analysts Offer Predictions for MNMD FY2026 Earnings

June 10, 2025 | marketbeat.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Recommendation of "Buy" by Brokerages

June 9, 2025 | marketbeat.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Shares Sold by Two Sigma Investments LP

June 5, 2025 | marketbeat.com

Millennium Management LLC Increases Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

June 5, 2025 | marketbeat.com

Why Mind Medicine Gave Investors a Powerful Buzz in May

June 4, 2025 | msn.com

Bank of America Corp DE Reduces Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

June 4, 2025 | marketbeat.com

Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade

June 2, 2025 | zacks.com

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 27, 2025 | finance.yahoo.com

HC Wainwright Has Pessimistic Outlook of MNMD Q3 Earnings

May 27, 2025 | marketbeat.com

What is HC Wainwright's Estimate for MNMD Q1 Earnings?

May 25, 2025 | marketbeat.com

Cantor Fitzgerald Has Negative View of MNMD FY2025 Earnings

May 25, 2025 | marketbeat.com

Northern Trust Corp Has $4.77 Million Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

May 24, 2025 | marketbeat.com

MindMed Announces New Employee Inducement Grants

May 19, 2025 | businesswire.com

Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?

May 13, 2025 | zacks.com

Why Mind Medicine (MindMed) Inc.’s (MNMD) Stock Is Up 5.37%

May 12, 2025 | aaii.com

Earnings call transcript: MindMed Q1 2025 results show mixed signals

May 10, 2025 | uk.investing.com

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

Mind Medicine (MindMed) Inc. 2025 Q1 - Results - Earnings Call Presentation

May 8, 2025 | seekingalpha.com

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

May 8, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNMD, GLPG, CNTA, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$16.71 -0.05 (-0.30%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$17.06 +0.34 (+2.06%)

As of 07:02 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Centessa Pharmaceuticals NASDAQ:CNTA

$13.00 +0.57 (+4.59%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$13.03 +0.03 (+0.22%)

As of 04:11 AM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Galapagos NASDAQ:GLPG

$27.05 -0.37 (-1.35%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$27.14 +0.09 (+0.34%)

As of 06:09 AM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Mind Medicine (MindMed) NASDAQ:MNMD

$6.64 -0.41 (-5.82%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$6.90 +0.26 (+3.90%)

As of 07:00 AM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time